reason report
medic continu drag pharma headwind persist
bottom line follow earn call remain
gener cautiou though quarterli adj ep result
ahead model earn margin remain
pressur view revis guid low qualiti
gener deflat headwind continu consist
previou quarter estim mean buy-sid econom
new gener launch enough off-set sell-sid price
pressur trend continu would expect y/i declin
pharma oper incom op
renew quarter describ fair
appropri oper incom guidanc reduc consider
medic due headwind within product divis
think mean patient recoveri busi lesser
extent cordi continu struggl maintain mp pt
disappoint perform medic highlight quarter
follow last quarter medic oper incom declin y/
segment declin anoth consider y/i
call manag highlight signific stride
made move sens urgenc address
opportun improv disappoint result attribut
primarili perform cardin health brand product tsa
transit creat back-offic connect issu higher back-ord
miss sale higher cost continu focu refin
commerci oper data capabl drive effici
address below-target servic level encourag hear
strateg account perform well
howev guidanc reduct neg
gener ration appear present major
headwind ask impact gener ration
manufactur exit certain product due declin price
manag sound optimist manag indic
overal number supplier appear decreas
howev discuss around manufactur ration
portfolio mention fda approv gener record
pace industri see intern particip
new older drug believ us pharma busi
remain pressur new gener launch buy effort
abl overcom sell-sid price pressur
understand mp outlook seem much favor
possibl cost-reduct effort sourc
net debt total capit
ep
year price history/av daili volume mil
compani inform svb leerink llc research
revenu present billion dollar
adj dilut ep continu oper
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
brand price increas expect manag
highlight brand inflat januari came expect
mention noth call pharma side
significantli better wors compani expect
expect guidanc manag next quarter
believ guid signific buy sell-sid
improv model flat pharma oper incom y/i basi
though could easili declin view especi
convers manufactur fruit posit
transpar ask scrutini surround rebat
hh propos manag mention contract expir
work word ensur protect case
sudden wac price chang would affect dollar earn
suggest still need earn dollar deserv
servic perform encourag hear
convers seem go well manufactur though
believ maintain buy-sid dollar valu becom
difficult industri continu face scrutini wac price out-
of-pocket cost patient
contract renew four year histor
revenu renew contract encourag
expect face margin pressur contract
howev encourag signific portion
busi renew next year full
year impact renew rate like creat
headwind guid next quarter
midpoint adj ep guid increas though remain gener
cautiou stock space beat quarter
manag increas low end ep guid
continu view beat rais rel low qualiti driven
tax would expect beat
impact guid manag also highlight
intent repay debt matur month june
continu maintain signific level scrutini select
come capit alloc overal disappoint
chang guidanc perform medic
pharma medic like continu face headwind
cost save opportun global product geographi
ration suppli chain optim sell strategi like
take time bear fruit
model updat maintain mp remain somewhat cautiou
follow view low qualiti quarter disappoint
expect estim
decreas reflect guid stock continu trade rel
low multipl may provid support maintain mp
pt stand
one largest pharmaceut distributor countri one
major cardin busi base pharmaceut distribut
medical-surg suppli distribut ancillari support servic jv
reli redoak drug purchas consortium sourc pharmaceut
product estim redoak gener market share allow sourc
product competit rate serv pharmaci specialti
pharmaci suppli relationship hospit util level
remain somewhat depress industri believ done good
job execut tuck-in acquisit grow footprint faster grow market segment
includ home health medic surgic distribut includ recent acquisit medtron
patient recoveri busi cordi addit though sold distribut busi
china compani retain presenc help sourc higher margin
prefer product add cardin product portfolio like cash-
flow characterist busi provid abil leverag larg fix
cost infrastructur model leverage- face sever on-going
headwind includ gener deflat risk brand inflat rate cordi integr
difficult commun investor challeng given system
challeng headwind market see abat time soon rate
share market perform
stock trade ep estim well
histor ntm price-to-earnings averag rel ep trade
trade next month
expect share trade ep would put stock
unchang headwind includ on-going gener deflat brand price drug price reform
possibl elimin rebat cordi given challeng risk
estim rate share mp
competit intens custom concentr high compet
op mp well sever smaller medical-
surgic distributor includ owen minor mp inc op
result competit custom buy-sid sell-sid may constantli tri
pressur margin novat premier larg custom present renew risk
lose custom custom put signific margin
pressur compani earn could come pressur
price could declin reform also pose risk price brand-
name drug gener declin time margin could come
pressur addit patient protect afford act health
educ reconcili act implement signific chang industri exampl
increas rebat paid manufactur fee must paid could
advers impact buy-sid margin abl earn addit retail
pharmaci face margin pressur due chang medicaid reimburs chang
awp could pressur compani sell-sid margin
regul extens drug distribut busi subject extens law
regul cover mani aspect compani oper includ fraud abus
law prescript drug pedigre track mani requir mandat
fda state feder law agenc compani requir hold
licens permit oper distribut center
tax posit pose risk oper mani state throughout
world tax law complex within intern perspect
addit ever refin lifo account could advers impact
inform system compani reli inform system within corpor
offic throughout distribut center technolog system complex
requir facilit purchas distribut thousand inventori line-item receiv
process ship order manag bill collect process payment mani
function reason technolog system fail function properli
earn could face substanti risk
acquisit integr could risk perform fair number
acquisit past sever year may continu acquir futur
compani fail integr acquisit onto platform
inform technolog personnel structur issu integr process
compani earn could risk
concentr supplier pose risk supplier make
revenu five supplier gener compani busi contract
typic written one-year basi automat renew year five year given
somewhat high degre concentr among manufactur
depend honor supplier agreement relationship
end deterior manufactur put price pressur
compani earn could risk addit depend raw
materi commod includ nuclear materi price oil impact distribut
econom trend compani global oper impact econom trend
exampl recess could caus patient less will go physician
offic certain procedur done out-of-pocket cost could view substanti
peopl unemploy worri becom unemploy howev
econom trend overal employ improv medical-surg distribut busi
incom statement model fiscal year end june
million
good sold
total revenu
total revenu
sale carefus stock
loss debt extinguish
weight average number share
incom statement model fiscal year end june
million
margin expans bp
margin expans bp
